Antitumor agent poly (amino acid) conjugates as a drug carrier in cancer chemotherapy

Yasunori Morimoto*, Kenji Sugibayashi, Satoshi Sugihara, Ken Ichi Hosoya, Sukekatsu Nozaki, Yoshihiro Ogawa

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Antitumor agent melphalan was conjugated through a carbodiimide-catalyzed reaction to poly (L-lysine) (71.3K and 2K) and poly (L-glutamic acid) (60K and 14K) at a ratio of approximately one molecule per 7-lysyl and 23-glutamate residues, respectively. These conjugates had 40 -70% of alkylating activities by themselves in vitro as compared with free melphalan. Poly (glutamic acid) conjugates showed the antitumor activity in vivo against Yoshida sarcoma in rats. In addition, poly (glutamic acid) conjugates containing 3H-phenylalanine which was used as a model compound instead of melphalan had a sustained release property of radioactivity and the release rates could be regulated by exopeptidases. After subcutaneous injection as the first choice of routes of administration, moreover, the conjugates were found to be absorbed through the lymphatic transport system, probably due to the macromolecularity. These results suggest that the melphalan-poly (amino acid) conjugates are one of good candidates to attain the sustained release and targeting of drugs in cancer chemotherapy.

Original languageEnglish
Pages (from-to)688-698
Number of pages11
JournalJournal of Pharmacobio-Dynamics
Volume7
Issue number9
DOIs
StatePublished - 1984

Keywords

  • antitumor activity
  • drug delivery system
  • drug-carrier conjugate
  • lymph concentration
  • melphalan
  • poly (amino acid)
  • poly (glutamic acid)
  • poly (lysine)
  • release

ASJC Scopus subject areas

  • Pharmacology

Fingerprint

Dive into the research topics of 'Antitumor agent poly (amino acid) conjugates as a drug carrier in cancer chemotherapy'. Together they form a unique fingerprint.

Cite this